Q32 Bio Inc. quarterly report, Q1 FY2020

Filing identity and reporting period

The supplied filing is Homology Medicines, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 7, 2020. This conflicts with the request metadata identifying Q32 Bio Inc.; the filing itself does not identify Q32 Bio. Verify the issuer before relying on this summary.

Business context

Homology was a clinical-stage genetic medicines company developing gene therapy and nuclease-free gene-editing treatments for rare genetic diseases. Its lead clinical program was HMI-102 for phenylketonuria (PKU); HMI-103 for PKU and HMI-202 for metachromatic leukodystrophy were in IND-enabling studies. The company had no approved products and no product-sales revenue.

Financial results and liquidity

Revenue was immaterial relative to operating expenses; profit and operating margins were negative, and a conventional revenue margin is not meaningful for this pre-commercial company. At March 31, 2020, cash and cash equivalents were $143.4 million, short-term investments $91.6 million, and restricted cash $1.3 million—$236.2 million combined. Total current assets were $238.3 million and current liabilities $17.5 million. The company reported no debt and an accumulated deficit of $235.0 million.

Management expected available cash, cash equivalents and short-term investments to fund operations into the fourth quarter of 2021, subject to assumptions that could prove inaccurate. The $115.0 million of investing cash inflow in Q1 2020 primarily reflected maturities of short-term investments, not operating cash generation. The company had a $150 million ATM facility available but made no sales under it in the quarter.

Changes versus prior comparable period

• Net loss increased by $11.5 million as operating expenses rose $11.7 million; R&D increased $8.8 million and G&A increased $2.9 million.
• R&D growth reflected higher HMI-102 trial and manufacturing costs, increased HMI-103/HMI-202 development, and additional employee-related costs. G&A growth included higher employee expenses, consulting and facility costs.
• Operating cash use increased $8.0 million year over year. Q1 2020 included substantial advance purchases of raw materials to reduce potential COVID-19 supply-chain disruption.
• Interest income declined to $1.2 million from $1.3 million, which management attributed to lower yields.
• Cash and cash equivalents rose from year-end while short-term investments fell, reflecting investment maturities and reallocation; combined cash, investments and restricted cash declined from $263.7 million at December 31, 2019 to $236.2 million at March 31, 2020.

Outlook, commentary and risks

• Management expected operating expenses and capital expenditures to increase as clinical and preclinical development, manufacturing scale-up, hiring and public-company costs continued. No specific earnings or revenue guidance was provided.
• The pheNIX Phase 1/2 trial was continuing, with measures intended to mitigate COVID-19 disruption, including home-health monitoring. Management cautioned that enrollment, trial conduct and completion could nevertheless be delayed and costs could rise. External preclinical studies were reported as progressing; the manufacturing facility was operating near normal levels.
• Management described preliminary HMI-102 data from three patients in the first two cohorts as showing tolerability without treatment-emergent adverse events or serious adverse events at the data cutoff, and an efficacy signal in the first mid-dose patient. These were early, limited observations, not confirmatory results.
• Major risks include clinical efficacy and safety uncertainty, regulatory and manufacturing challenges, reliance on suppliers and collaborators, COVID-19 effects, and the need for future capital. The Novartis collaboration could provide up to $530 million in contingent milestones plus royalties, but these amounts were not assured; Novartis had discontinued the sickle-cell program in 2019 and could terminate target programs for convenience.
• The company adopted lease accounting standard ASC 842 on January 1, 2020, recording $6.8 million of right-of-use assets and $17.7 million of lease liabilities at adoption; adoption did not materially affect the income statement. March 31 operating lease liabilities were $17.2 million.
• Management reported disclosure controls effective at March 31, 2020 and no material legal proceedings. It had completed the first phase of an enterprise resource planning system implementation and was monitoring related controls.

Important facts to verify

• Confirm issuer identity: the filing is for Homology Medicines, Inc., not Q32 Bio Inc.
• Check whether the reported fourth-quarter 2021 cash runway remains reasonable under current spending, trial progress and financing assumptions.
• Verify subsequent HMI-102 clinical data, patient enrollment and any COVID-19-related changes to trial timing or costs.
• Assess cash burn and the extent to which elevated Q1 raw-material purchases were one-time or recurring.
• Review actual use of the $150 million ATM and any other financing, dilution or changes to the share count after the reporting date.
• Evaluate Novartis program status and the conditions and likelihood of any collaboration milestones or royalties.